The Cassava Sciences saga: Short sellers, ‘gaming’ the FDA, and the damaging ripple effects

Stocks down

The Federal Drug Administration’s decision last month to deny a citizen petition on behalf of short sellers with positions in Cassava Sciences stock highlights the damage the commonly exploited regulatory process can have on a company, regardless of innocence or guilt.

THIS IS MEMBERS-ONLY CONTENT

SINGLE MEMBERSHIP                                             CORPORATE MEMBERSHIP

You are not logged in and do not have access to members-only content.

If you are already a registered user or a member, SIGN IN now.